GlaxoSmithKline plc GLAXF · Stock Open GlaxoSmithKline plc in new tab
GlaxoSmithKline plc Analysis (GLAXF)
Is GlaxoSmithKline plc a good investment? GlaxoSmithKline plc (GLAXF) is currently trading at 26.63 USD.
In terms of valuation, the stock trades at a P/E ratio of 12.70. This relatively low multiple may signal that GlaxoSmithKline plc is undervalued compared to historical market norms.
Earnings Schedule: GlaxoSmithKline plc is expected to release its next earnings report on July 29, 2026. The market consensus estimate for Forward EPS is 2.20.
For income investors, GlaxoSmithKline plc pays a dividend yield of 3.38%. With a payout ratio of 45%, the dividend appears sustainable.
Investor FAQ
Does GlaxoSmithKline plc pay a dividend?
Yes, it pays an annual dividend of 0.67 USD (3.38% yield).
What asset class is GlaxoSmithKline plc?
GlaxoSmithKline plc is classified as a Stock. You can compare it against 8 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be July 29, 2026. The company currently has a trailing EPS of 1.91.
Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
| Year | Total Dividends |
|---|---|
| ▸2027 |
0.43 USD
|
| April 8, 2027 (estimated) | 0.2328 |
| Jan. 14, 2027 (estimated) | 0.1930 |
| ▸2026 |
1.11 USD
|
| Oct. 8, 2026 (estimated) | 0.2061 |
| July 9, 2026 | 0.2266 |
| July 9, 2026 | 0.2290 |
| April 9, 2026 | 0.2451 |
| Jan. 8, 2026 | 0.2059 |
| ▸2025 |
0.82 USD
|
| Oct. 9, 2025 | 0.2170 |
| July 10, 2025 | 0.2121 |
| April 10, 2025 | 0.2022 |
| Jan. 9, 2025 | 0.1894 |
| ▸2024 |
0.76 USD
|
| Oct. 10, 2024 | 0.1936 |
| July 11, 2024 | 0.1901 |
| April 11, 2024 | 0.2020 |
| Jan. 11, 2024 | 0.1738 |
| ▸2023 |
0.68 USD
|
| Oct. 12, 2023 | 0.1784 |
| July 13, 2023 | 0.1750 |
| April 13, 2023 | 0.1660 |
| Jan. 12, 2023 | 0.1640 |
| ▸2022 |
0.94 USD
|
| Oct. 6, 2022 | 0.1960 |
| July 1, 2022 | 0.1730 |
| April 7, 2022 | 0.3110 |
| Jan. 13, 2022 | 0.2560 |
| ▸2021 |
1.10 USD
|
| Oct. 7, 2021 | 0.2610 |
| July 8, 2021 | 0.2680 |
| April 8, 2021 | 0.3190 |
| Jan. 14, 2021 | 0.2510 |
| ▸2020 |
1.02 USD
|
| Oct. 8, 2020 | 0.2480 |
| July 9, 2020 | 0.2320 |
| April 9, 2020 | 0.2970 |
| Jan. 9, 2020 | 0.2440 |
| ▸2019 |
0.84 USD
|
| Oct. 10, 2019 | 0.2310 |
| July 11, 2019 | 0.1900 |
| April 11, 2019 | 0.2300 |
| Jan. 10, 2019 | 0.1900 |
| ▸2018 |
1.07 USD
|
| Oct. 11, 2018 | 0.2450 |
| July 12, 2018 | 0.2570 |
| April 12, 2018 | 0.3200 |
| Jan. 11, 2018 | 0.2490 |
| ▸2017 |
1.01 USD
|
| Oct. 12, 2017 | 0.2470 |
| July 13, 2017 | 0.2460 |
| April 13, 2017 | 0.2860 |
| Jan. 12, 2017 | 0.2340 |
| ▸2016 |
1.14 USD
|
| Oct. 13, 2016 | 0.2462 |
| July 14, 2016 | 0.2750 |
| April 14, 2016 | 0.3304 |
| Jan. 14, 2016 | 0.2887 |
| ▸2015 |
1.29 USD
|
| Oct. 1, 2015 | 0.2963 |
| July 9, 2015 | 0.2996 |
| April 9, 2015 | 0.3940 |
| Jan. 8, 2015 | 0.3022 |
| ▸2014 |
1.33 USD
|
| Oct. 2, 2014 | 0.3198 |
| July 10, 2014 | 0.3189 |
| April 10, 2014 | 0.3844 |
| Jan. 9, 2014 | 0.3038 |
| ▸2013 |
1.18 USD
|
| Oct. 3, 2013 | 0.2792 |
| July 11, 2013 | 0.2801 |
| April 11, 2013 | 0.3366 |
| Jan. 3, 2013 | 0.2852 |
| ▸2012 |
0.95 USD
|
| Oct. 4, 2012 | 0.2662 |
| July 5, 2012 | 0.2742 |
| April 12, 2012 | 0.4081 |
| ▸2011 |
0.60 USD
|
| Nov. 2, 2011 | 0.1511 |
| Aug. 3, 2011 | 0.1422 |
| May 4, 2011 | 0.1422 |
| Feb. 9, 2011 | 0.1689 |
| ▸2010 |
0.51 USD
|
| Oct. 27, 2010 | 0.1280 |
| July 28, 2010 | 0.1200 |
| May 5, 2010 | 0.1200 |
| Feb. 10, 2010 | 0.1440 |
| ▸1997 |
0.30 USD
|
| May 20, 1997 | 0.3024 |
| ▸1996 |
0.46 USD
|
| Oct. 1, 1996 | 0.2326 |
| May 20, 1996 | 0.2293 |
| ▸1995 |
0.46 USD
|
| Oct. 23, 1995 | 0.3093 |
| April 10, 1995 | 0.1556 |
| ▸1994 |
0.42 USD
|
| Nov. 21, 1994 | 0.2827 |
| April 11, 1994 | 0.1338 |
| ▸1993 |
0.33 USD
|
| Nov. 19, 1993 | 0.2299 |
| April 30, 1993 | 0.1005 |
| ▸1992 |
0.29 USD
|
| Nov. 13, 1992 | 0.1900 |
| May 1, 1992 | 0.1047 |
| ▸1991 |
0.50 USD
|
| Nov. 21, 1991 | 0.3388 |
| May 22, 1991 | 0.1584 |
| ▸1990 |
0.22 USD
|
| Nov. 26, 1990 | 0.1500 |
| June 8, 1990 | 0.0700 |
| ▸1989 |
0.53 USD
|
| Nov. 10, 1989 | 0.2500 |
| May 8, 1989 | 0.1000 |
| Jan. 3, 1989 | 0.1800 |
| ▸1988 |
0.21 USD
|
| May 20, 1988 | 0.0700 |
| Jan. 4, 1988 | 0.1400 |
| ▸1987 |
0.05 USD
|
| June 19, 1987 | 0.0500 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| GlaxoSmithKline plc | Jul 09, 2026 | Upcoming | 0.2266 USD |
| GlaxoSmithKline plc | Jul 09, 2026 | Upcoming | 0.22899 USD |
| GlaxoSmithKline plc | Apr 09, 2026 | Paid | 0.24511 USD |
| GlaxoSmithKline plc | Jan 08, 2026 | Paid | 0.2059 USD |
| GlaxoSmithKline plc | Oct 09, 2025 | Paid | 0.217 USD |
| Split Date | Split Ratio to 1 |
|---|---|
| July 19, 2022 | 0.800000 |
Community Discussion